Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 5

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 5
---
 in a position where they have invested in us, but we have not raised sufficient proceeds in this offering to adequately fund the intended uses of the proceeds as described in this prospectus.

#### PerShare of Common Stock andSeries WarrantsPer Pre-FundedWarrant andSeries WarrantsTotalPublic offering price​$​$​$​Placement Agent fees(1)​​​​​​​Proceeds, before expenses, to us(2)​$​$​$​(1)We have agreed to pay Dawson James a total cash fee equal to 8% of the aggregate gross proceeds raised in this offering and to reimburse Dawson James for its legal fees and expenses and other out-of-pocket expenses in an amount up to $125,000. See “Plan of Distribution” for a description of the compensation to be received by Dawson James.(2)Because there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above. In addition, this does not include proceeds from the cash exercise of the Pre-Funded Warrants, if any, or Series Warrants. For more information, see “Plan of Distribution.”Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page12of this prospectus and elsewhere in this prospectus for a discussion of information that should be considered in connection with an investment in our securities.Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is not permitted.Delivery of the securities offered hereby is expected to be made on or about         , 2025, subject to satisfaction of certain customary closing conditions.Dawson James Securities, Inc.The date of this prospectus is       , 2025.​​
Table of Contents

|                                                                  |   ​ |
| ABOUT THIS PROSPECTUS                                            |  ii |
| ​                                                                |   ​ |
| SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS                |   1 |
| ​                                                                |   ​ |
| PROSPECTUS SUMMARY                                               |   3 |
| ​                                                                |   ​ |
| SUMMARY OF THE OFFERING                                          |   9 |
| ​